

Dear Editors,

Thank you for your edition and for the reviewers' comments concerning our manuscript NO. 41563 .

We have studied your and reviewers' comments carefully and have made correction which we hope meet with approval. Revised portion are marked in red in the paper. All the corrections in the manuscript and the responds to you and the reviewers' comments are described below.

Responses to editors:

Thank you for giving us so many good comments. According to your comments, we added running title, author information, core tip and audio core tip, 2 tables, and modified format of manuscript and reference. We also prepared conflict interest statement and copyright license agreement to submit according to your comments.

Response to reviewers:

Reviewer: #1

[Comment 1] This is a very useful guideline , providing evidence- and experience-based expert recommendations on the management of TKI-associated side effects in GIST patients. Your abstract summarize and reflect the the main body of the manuscript.

[Answer 1] Thank you for giving our paper so many positive evaluation.

Reviewer: #2

[Comment 1] Dear Authors, I read your manuscript namely "Chinese consensus of management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumor". Side effects and its management of the TKI

treatment in the patients with GIST were reviewed. Overall it is a globally good presented study with an interesting topic. Title, abstract and keywords are well described and clear. Conclusions are justifiable and prudent enough. But in the methods it has some major deficiencies. In the text, it was said that this manuscript is consensus guidelines and results from expert panel discussion. But in the text, the strength and quality of the evidences and recommendations were not mentioned. Did GRADE system be used in the study (necessary for guidelines). in this situation, this manuscript is a only review.

[Answer 1] Thank you for your good comments and good evaluation. I agree with you about the strength and quality of the evidences and recommendations. Every author added the strength of recommendations after each management suggestion according to GRADE system. We also added the description of the method in second paragraph and corresponding reference in Reference section.

Reviewer: #3

[Comment 1] The authors conducted a review regarding the management of side effects of TKI treatment in patients with GIST. Although this article is concise and informative, I have a minor suggestion to this article. 1. Because the prevalence of HBV infection is about 10% in China, the authors should consider the issue of TKI-related HBV reactivation in patients receiving TKI treatment. In addition to the topic of TKI related hepatotoxicity, please add a paragraph discussing this issue.

[Answer 1] Thank you for your good comments and good evaluation. We added the content of TKI-related HBV reaction and discussion paragraph.

In all, we found your comments are quite helpful. Thank you very much.

Yours sincerely,

Hui Cao